International Stroke Conference 2025  /  New Horizons in Medical Therapy for Stroke Prevention  /  Emerging Antithrombotic Options for Stroke Prevention
Logo

American Heart Association

  6
  0

Final ID:

Emerging Antithrombotic Options for Stroke Prevention

  • Shoamanesh, Ashkan  ( MCMASTER UNIVERSITY , Hamilton , Ontario , Canada )
    • Author Disclosures:
    Ashkan Shoamanesh: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Daiichi Sankyo:Active (exists now) ; Consultant:Bioxides:Past (completed) ; Speaker:Bayer AG:Active (exists now) ; Speaker:Daiichi Sankyo:Active (exists now) ; Speaker:AstraZeneca:Active (exists now) ; Consultant:Bayer AG:Active (exists now) ; Consultant:Daiichi Sankyo:Active (exists now)
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

New Horizons in Medical Therapy for Stroke Prevention

Thursday, 02/06/2025 , 04:45PM - 05:45PM

ISC Invited Symposium

More abstracts on this topic:
Emerging Options for Dyslipidemia Treatment

Dafer Rima, Lutsep Helmi

Anti-Inflammatory Medications for Stroke Prevention

Kapral Moira, Katsanos Aristeidis

More abstracts from these authors:
Antithrombotic treatment in ICH: Perspectives from Vascular Neurology

Shoamanesh Ashkan, Al-shahi Salman Rustam

Pro: Andexanet alfa is Preferred over PCC for Reversal of FXa Inhibitor Associated ICH

Shoamanesh Ashkan, Goldstein Joshua, Christensen Hanne, Seiffge David, Siegal Deborah

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)